Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Oncolytic viruses
Treatment Talimogene laherparepvec
Drugstatus Approved, Experimental, Investigational
Drugbank ID DB13896
Checkpoints NA
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_R_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trail phase 1b
Description We observed broad changes in tumor inflammation after talimogene laherparepvecat week 6, including increased infiltration by immune cells anda clear increase in cells expressing PD-L1 in eight out of teninjected tumors and in two out of four noninjected tumors.
PMID 28886381
Title Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy